Cathie Wood Just Wrote Another Check for Rocket Lab. NASA Gave the Big Mars Job to Blue Origin.
Rocket Lab (RKLB) is living two stories at once, and they do not rhyme.
On one side, NASA handed Blue Origin a Mars telecommunications orbiter contract with a maximum potential value near $700 million. Rocket Lab was eligible to compete. It did not win the lane. Sentiment already fragile after a long drawdown from the highs took another hit.
On the other side, Cathie Wood's ARK Invest kept buying. Recent disclosures show roughly $31.6 million of Rocket Lab shares across ARK funds on one session, on top of about $12.8 million the day before. Two-day buying landed near 700,000 shares and roughly $44 million of stock while the price sat in the low $60s.
That is the whole controversy in one frame. A celebrity growth buyer is pressing the accelerator while a flagship civil-space award walks out the door.
The Stock Already Paid for Doubt
RKLB closed near $62.54 on September 1, down again on the session and sitting more than 50% below its 52-week high near $151. This is not a gentle pullback. This is a stock that already took the market's skepticism in cash.
Operationally the company still posts loud numbers. Second-quarter revenue hit about $234 million, up 62% year over year. Backlog stood near $2.36 billion, up 137%. Management has talked about more than 90 missions in the launch book and a growing space-systems business next to Electron and the Neutron medium-lift bet.
Markets can respect a backlog and still punish a timeline. Neutron remains the long-duration swing factor. Delays, margin guides that look softer near term, and now a high-profile NASA miss give bears a simple sentence: the story slipped.
Why ARK's Buy Matters Anyway
Cathie Wood does not move every ticker she touches, and copy-trading a famous manager is a weak plan. What the buy does show is that at least one high-profile growth shop thinks the selloff overshot the damage.
ARK has been adding Rocket Lab in size across recent sessions while trimming other names. That is a portfolio vote, not a press release. It says the firm still wants commercial launch and space systems exposure even after the stock lost more than half its peak value.
The bull case ARK is underwriting looks familiar if you have followed the name. Electron cadence, defense and government work including earlier Space Force awards, a fat backlog, and the chance Neutron eventually turns Rocket Lab into more than a small-launcher story. The bear case is just as plain. Execution risk on the next vehicle, competition from deep-pocketed rivals, and the habit public markets have of crushing unprofitable aerospace dreams when the calendar slips.
The NASA Snub Is a Sentiment Tax
A $700 million ceiling award to Blue Origin is not a death certificate for Rocket Lab. One contract does not zero out a $2.36 billion backlog. It does change the tone. NASA choosing the Jeff Bezos-backed competitor for a Mars communications job hands every skeptic a clean headline: when the civil prize got serious, Rocket Lab was not the pick.
That tax shows up in the chart before it shows up in next quarter's revenue. Investors who bought the Space Force glow earlier this year now have to hold a name that can win military work and still lose a flashy NASA lane in the same season. Both facts can sit on the same balance sheet. The stock is arguing about which one matters more for the multiple.
Bottom Line
Rocket Lab is caught between a real backlog and a real narrative hit. NASA's Blue Origin Mars award stings. Cathie Wood's fresh eight-figure buying says ARK still sees a mispriced long-duration space compounder under $65. For self-directed investors, do not outsource the decision to either headline. Watch Neutron milestones, backlog conversion, and whether defense wins keep offsetting civil-space misses. If execution stabilizes, this drawdown is inventory. If the calendar keeps slipping, famous buyers will not be enough to hold the floor.